- $138.74m
- -$207.11m
- 34
- 50
- 35
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.43 | ||
| Price to Tang. Book | 0.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.74% | ||
| Return on Equity | -50.35% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 1.67 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 1st, 2015
- Public Since
- September 26th, 2024
- No. of Shareholders
- 102
- No. of Employees
- 62
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 35,850,037
- Address
- 1445A South 50Th Street, RICHMOND, 94804
- Web
- https://bioagelabs.com
- Phone
- +1 5108061445
- Auditors
- KPMG LLP
Upcoming Events for BIOA
Similar to BIOA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the BioAge Labs share price?
As of Today at 19:35 UTC, shares in BioAge Labs are trading at $3.87. This share price information is delayed by 15 minutes.
How has the BioAge Labs share price performed this year?
Shares in BioAge Labs last closed at $3.87 and the price had moved by over the past 365 days. In terms of relative price strength the BioAge Labs share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for BioAge Labs?
The overall consensus recommendation for BioAge Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioAge Labs dividend yield?
BioAge Labs does not currently pay a dividend.
Does BioAge Labs pay a dividend?
BioAge Labs does not currently pay a dividend.
When does BioAge Labs next pay dividends?
BioAge Labs does not currently pay a dividend.
How do I buy BioAge Labs shares?
To buy shares in BioAge Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioAge Labs?
As of the previous close price of $3.87, shares in BioAge Labs had a market capitalisation of $138.74m.
Where are BioAge Labs shares listed?
Here are the trading details for BioAge Labs:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BIOA
What kind of share is BioAge Labs?
Based on an overall assessment of its quality, value and momentum BioAge Labs is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioAge Labs share price forecast for 2025?
The analyst consensus target price for shares in BioAge Labs is $5.67. That is 46.51% above the last closing price of $3.87.
Analysts covering BioAge Labs currently have a consensus Earnings Per Share (EPS) forecast of -$2.13 for the next financial year.
Find out moreWhat is the trend in the BioAge Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioAge Labs. Over the past six months, its share price has underperformed the S&P500 Index by -82.03%.
As of the last closing price of $3.87, shares in BioAge Labs were trading -63.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioAge Labs PE Ratio?
The BioAge Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioAge Labs?
We do not have data on BioAge Labs' directors